Diagnostic Value of 16S Ribosomal RNA Gene Polymerase Chain Reaction/Sanger Sequencing in Clinical Practice.


Journal

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213

Informations de publication

Date de publication:
15 09 2021
Historique:
received: 05 11 2020
pubmed: 19 8 2021
medline: 8 10 2021
entrez: 18 8 2021
Statut: ppublish

Résumé

Accurate microbiologic diagnosis is important for appropriate management of infectious diseases. Sequencing-based molecular diagnostics are increasingly used for precision diagnosis of infections. However, their clinical utility is unclear. We conducted a retrospective analysis of specimens that underwent 16S ribosomal RNA (rRNA) gene polymerase chain reaction (PCR) followed by Sanger sequencing at our institution from April 2017 through March 2019. A total of 566 specimens obtained from 460 patients were studied. Patients were considered clinically infected or noninfected based on final diagnosis and management. In 17% of patients, 16S rRNA PCR/sequencing was positive and in 5% of patients, this test led to an impact on clinical care. In comparison, bacterial cultures were positive in 21% of patients. Specimens with a positive Gram stain had 12 times greater odds of having a positive molecular result than those with a negative Gram stain (95% confidence interval for odds ratio, 5.2-31.4). Overall, PCR positivity was higher in cardiovascular specimens (37%) obtained from clinically infected patients, with bacterial cultures being more likely to be positive for musculoskeletal specimens (P < .001). 16S rRNA PCR/sequencing identified a probable pathogen in 10% culture-negative specimens. 16S rRNA PCR/sequencing can play a role in the diagnostic evaluation of patients with culture-negative infections, especially those with cardiovascular infections.

Sections du résumé

BACKGROUND
Accurate microbiologic diagnosis is important for appropriate management of infectious diseases. Sequencing-based molecular diagnostics are increasingly used for precision diagnosis of infections. However, their clinical utility is unclear.
METHODS
We conducted a retrospective analysis of specimens that underwent 16S ribosomal RNA (rRNA) gene polymerase chain reaction (PCR) followed by Sanger sequencing at our institution from April 2017 through March 2019.
RESULTS
A total of 566 specimens obtained from 460 patients were studied. Patients were considered clinically infected or noninfected based on final diagnosis and management. In 17% of patients, 16S rRNA PCR/sequencing was positive and in 5% of patients, this test led to an impact on clinical care. In comparison, bacterial cultures were positive in 21% of patients. Specimens with a positive Gram stain had 12 times greater odds of having a positive molecular result than those with a negative Gram stain (95% confidence interval for odds ratio, 5.2-31.4). Overall, PCR positivity was higher in cardiovascular specimens (37%) obtained from clinically infected patients, with bacterial cultures being more likely to be positive for musculoskeletal specimens (P < .001). 16S rRNA PCR/sequencing identified a probable pathogen in 10% culture-negative specimens.
CONCLUSION
16S rRNA PCR/sequencing can play a role in the diagnostic evaluation of patients with culture-negative infections, especially those with cardiovascular infections.

Identifiants

pubmed: 34407178
pii: 6354408
doi: 10.1093/cid/ciab167
pmc: PMC8442790
doi:

Substances chimiques

DNA, Bacterial 0
RNA, Ribosomal, 16S 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

961-968

Subventions

Organisme : NIAMS NIH HHS
ID : R01 AR056647
Pays : United States
Organisme : National Institute of Allergy and Infectious Diseases

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Références

J Clin Microbiol. 2003 Sep;41(9):4435-7
pubmed: 12958286
Open Forum Infect Dis. 2018 Oct 10;5(11):ofy257
pubmed: 30539032
J Clin Microbiol. 2012 Jul;50(7):2250-4
pubmed: 22553237
Medicine (Baltimore). 2007 Jul;86(4):195-202
pubmed: 17632260
J Clin Microbiol. 2018 Apr 25;56(5):
pubmed: 29444832
Med Mal Infect. 2020 Feb;50(1):63-73
pubmed: 31611135
JB JS Open Access. 2018 Jul 12;3(3):e0060
pubmed: 30533595
Medicine (Baltimore). 2017 Nov;96(47):e8392
pubmed: 29381916
Pharmacotherapy. 2019 Mar;39(3):261-270
pubmed: 30506852
Clin Infect Dis. 2020 Sep 12;71(6):1554-1557
pubmed: 31907545
Clin Microbiol Infect. 2004 Jun;10(6):579-81
pubmed: 15191390
BMC Musculoskelet Disord. 2016 Mar 25;17:138
pubmed: 27015812
APMIS. 2008 Mar;116(3):190-8
pubmed: 18377584
Clin Microbiol Infect. 2019 Nov;25(11):1447-1448
pubmed: 31306789
Interact Cardiovasc Thorac Surg. 2015 May;20(5):589-93
pubmed: 25678629
Chest. 2016 Dec;150(6):1251-1259
pubmed: 27615024
J Hosp Infect. 2018 Jun;99(2):148-152
pubmed: 28838799
Clin Infect Dis. 2003 Jul 15;37(2):167-72
pubmed: 12856207
J Clin Microbiol. 2005 Feb;43(2):615-9
pubmed: 15695654
Clin Microbiol Rev. 2004 Oct;17(4):840-62, table of contents
pubmed: 15489351
Diagn Microbiol Infect Dis. 2011 Feb;69(2):153-60
pubmed: 21251558
J Clin Microbiol. 2014 Oct;52(10):3583-9
pubmed: 25056331
BMC Infect Dis. 2012 Nov 24;12:321
pubmed: 23176603
Kaohsiung J Med Sci. 2018 Feb;34(2):71-78
pubmed: 29413230
Knee Surg Relat Res. 2017 Sep 1;29(3):155-164
pubmed: 28854760
Emerg Infect Dis. 2003 Dec;9(12):1543-7
pubmed: 14720393
Acad Emerg Med. 2010 Jul;17(7):741-7
pubmed: 20653589
Mol Diagn. 2001 Dec;6(4):313-21
pubmed: 11774196
Acta Orthop. 2005 Jun;76(3):341-6
pubmed: 16156461
Ann Lab Med. 2020 Jan;40(1):63-67
pubmed: 31432641
Can J Infect Dis Med Microbiol. 2013 Summer;24(2):85-8
pubmed: 24421807
J Infect Public Health. 2020 Jul;13(7):998-1002
pubmed: 32061569
Clin Infect Dis. 2007 Jan 1;44(1):87-93
pubmed: 17143822
Clin Infect Dis. 2019 Aug 30;69(6):938-940
pubmed: 30535353
Emerg Infect Dis. 2017 Nov;23(11):1864-1866
pubmed: 29048278
J Microbiol Methods. 2006 Dec;67(3):574-81
pubmed: 16859787
J Clin Microbiol. 2012 Mar;50(3):583-9
pubmed: 22170934
Int J Infect Dis. 2017 Apr;57:144-149
pubmed: 28216180
J Clin Microbiol. 2017 Sep;55(9):2599-2608
pubmed: 28659319
Clin Infect Dis. 2010 Jul 15;51(2):131-40
pubmed: 20540619
Infection. 2015 Oct;43(5):551-60
pubmed: 26021312

Auteurs

Madiha Fida (M)

Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.

Sarwat Khalil (S)

Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Division of Infectious Disease and International Medicine, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.

Omar Abu Saleh (O)

Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Douglas W Challener (DW)

Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Muhammad Rizwan Sohail (MR)

Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Division of Infectious Disease, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.

Joshua N Yang (JN)

Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.

Bobbi S Pritt (BS)

Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.

Audrey N Schuetz (AN)

Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.

Robin Patel (R)

Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH